PMV Pharma Finalizes $50.8M Offering with FDA-Linked Warrant Reset Terms
PMVP sits 25% above its 52-week low of $1.02 on elevated volume (17× avg).
Summary
PMV Pharma finalized a $50.8 million offering with warrants carrying FDA-linked exercise price reset terms. Net proceeds of $47 million extend cash runway into Q1 2028, addressing the going concern warning from Q2.
Key Events · Financing and Capital Events · PMVP
-
Offering Finalized at $50.8M
Underwriting agreement signed with TD Securities for 22,055,000 shares, 19,900,000 pre-funded warrants, and 41,955,000 common warrants at $1.21 per share/warrant combination.
-
Net Proceeds $47M
After underwriting discounts and expenses, net proceeds estimated at $47.0 million, funding operations into Q1 2028 per company guidance.
-
FDA-Linked Warrant Reset
Warrant exercise price resets to the greater of 33% of initial price or 5-day VWAP following FDA NDA acceptance announcement, with share count increasing proportionally.
-
Mandatory Exercise Provision
Company can force exercise of up to 50% of warrants within 30-60 days of positive FDA decision, with unexercised warrants becoming void.
Analysis · PMVP · Life Sciences
PMV Pharmaceuticals finalized a $50.8 million underwritten offering priced at $1.21 per share with warrants, adding critical new details to the deal announced two days ago. The offering includes 22.1 million shares, 19.9 million pre-funded warrants, and 41.9 million common warrants. The most significant new element is a warrant exercise price reset mechanism tied to FDA acceptance of the company's NDA for rezatapopt — if the FDA accepts the application, the exercise price drops to the greater of 33% of the initial price or the 5-day VWAP following the announcement, with a corresponding increase in warrant share count. The company can also force exercise of up to 50% of warrants within 30-60 days of a positive FDA decision. Net proceeds of approximately $47 million will fund operations into Q1 2028, addressing the going concern warning disclosed in the Q2 10-Q. The offering is highly dilutive — the 41.9 million common warrants alone represent potential issuance exceeding the current share count — but the capital is essential for the company's survival runway.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.3% of the 1324 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMVP was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69M. The 52-week trading range was $1.02 to $1.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.